Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Name: Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Author: Dunleavy, Kieron

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. — المؤلف: Dunleavy, Kieron — The Lancet. Haematology 20181231

المؤلف: Dunleavy, Kieron
النشر: The Lancet. Haematology 20181231
الوصف: e609-e617 p.
الموضوعات: Adult؛ Aged؛ Aged, 80 and over؛ Antineoplastic Combined Chemotherapy Protocols؛ Cyclophosphamide؛ Dose-Response Relationship, Drug؛ Doxorubicin؛ Etoposide